Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Buy" by Brokerages

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $27.17.

Several research analysts have recently issued reports on IMNM shares. Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Immunome in a research note on Monday. Piper Sandler lowered their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Finally, Lifesci Capital assumed coverage on Immunome in a research report on Tuesday. They set an "outperform" rating and a $20.00 price objective for the company.

Insider Activity

In other news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 8.60% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMNM. Enavate Sciences GP LLC purchased a new stake in shares of Immunome in the fourth quarter valued at $36,939,000. JPMorgan Chase & Co. boosted its stake in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after buying an additional 624,045 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after buying an additional 324,614 shares during the period. Granahan Investment Management LLC acquired a new position in shares of Immunome during the 4th quarter valued at about $3,337,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Immunome by 2,696.5% during the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock worth $3,356,000 after acquiring an additional 304,700 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Trading Down 2.4 %

Shares of NASDAQ IMNM traded down $0.21 during midday trading on Tuesday, reaching $8.64. 45,067 shares of the company were exchanged, compared to its average volume of 906,241. Immunome has a 1 year low of $8.51 and a 1 year high of $26.70. The stock has a fifty day simple moving average of $10.13 and a 200 day simple moving average of $11.94. The stock has a market cap of $688.95 million, a P/E ratio of -1.06 and a beta of 1.93.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads